Outcome On Renal Function of an Everolimus Based Therapy After Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 5 Year Data of the APOLLO Trial.

被引：1
|
作者：
Arns, W. [1 ]
Rath, T. [1 ]
Sommerer, C. [1 ]
Reinke, P. [1 ]
Haller, H. [1 ]
Suwelack, B. [1 ]
Huppertz, A. [1 ]
Porstner, M. [2 ]
Baeumer, D. [2 ]
Paulus, E. [2 ]
Witzke, O. [1 ]
Budde, K. [1 ]
机构：
[1] Apollo Study Grp, Nurnberg, Germany
[2] Novartis Pharmaceut, Nurnberg, Germany
来源：
TRANSPLANTATION | 2014年 / 98卷
关键词：
D O I：
10.1097/00007890-201407151-00448
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
2920
引用
下载
收藏
页码：145 / 145
页数：1
相关论文
共 50 条
  • [41] IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 3 YEAR FOLLOW-UP OF THE ZEUS TRIAL
    Lehner, Frank
    Budde, Klemens
    Arns, Wolfgang
    Sommerer, Claudia
    Reinke, Petra
    Eisenberger, Ute
    Vogel, Eva-Maria
    Scheidl, Stefan
    Witzke, Oliver
    TRANSPLANT INTERNATIONAL, 2011, 24 : 57 - 57
  • [42] Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor
    Eisenberger, Ute
    Sollinger, Daniel
    Stickel, Felix
    Burckhardt, Beat
    Frey, Felix J.
    CLINICAL TRANSPLANTATION, 2009, 23 (04) : 499 - 504
  • [43] POST HOC SUBGROUP ANALYSIS OF ZEUS: OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION FROM A CALCINEURIN INHIBITOR TO AN EVEROLIMUS BASED REGIMEN: 5 YEAR FOLLOW-UP DATA
    Lehner, F.
    Budde, K.
    Suwelack, B.
    Arns, W.
    Wuethrich, R. P.
    Reinke, P.
    Muehlfeld, A.
    Eisenberger, U.
    Stahl, R.
    Porstner, M.
    Heller, K.
    Wolters, H. H.
    Witzke, O.
    Hauser, I. A.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 58 - 58
  • [44] Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
    Lehner, F.
    Budde, K.
    Wuethrich, R.
    Reinke, P.
    Arns, W.
    Muehlfeld, A.
    Eisenberger, U.
    Stahl, R.
    Heller, K.
    Witzke, O.
    Suwelack, B.
    Wolters, H.
    Hauser, I.
    Porstner, M.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [45] Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients: 5 Years Follow-Up of the ZEUS Trial
    Budde, K.
    Witzke, O.
    Sommerer, C.
    Reinke, P.
    Eisenberger, U.
    Paulus, E.
    Porstner, M.
    May, C.
    Arns, W.
    Lehner, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 35 - 36
  • [46] The PROTECT study: Renal function benefit with everolimus versus calcineurin inhibitor-based therapy was maintained over 35 months in liver transplant recipients
    Schlitt, Hans J.
    Kaiser, Gernot M.
    Richter, Nicolas
    Heyne, Nils
    Rauchfuss, Falk
    Neuhaus, Peter
    Schemmer, Peter
    Fischer, Lutz
    Paulus, Eva-Maria
    Mertens, Michael
    Sterneck, Martina
    HEPATOLOGY, 2012, 56 (06) : 1531 - 1532
  • [47] Everolimus for Calcineurin-Inhibitor Minimization in Lung Transplant Recipients With Chronic Renal Insufficiency: Four-Year Outcomes
    Schoeppler, K. E.
    Lyu, D. M.
    Vandervest, K. M.
    Grazia, T. J.
    Crossno, J. T.
    Zamora, M. R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S244 - S244
  • [48] EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR EXPOSURE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: EFFICACY, SAFETY AND RENAL FUNCTION OUTCOME FROM THE TRANSFORM STUDY
    Sommerer, C.
    Arns, W.
    Weithofer, P.
    Lehner, F.
    Banas, B.
    van der Giet, M.
    Habicht, A.
    Renders, L.
    Rath, T.
    Bartels, M.
    Pratschke, J.
    Hessel, K.
    Bernhardt, P.
    Witzke, O.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 18 - 19
  • [49] CLINICAL OUTCOME OF CALCINEURIN INHIBITOR FREE THERAPY WITH EVEROLIMUS AND MYCOPHENOLIC ACID DERIVATES IN MAINTENANCE HEART TRANSPLANT RECIPIENTS WITH CHRONIC RENAL FAILURE: A SIX MONTH FOLLOW-UP
    Fuchs, U.
    Zittermann, A.
    Schulze, B.
    Hakim-Meibodi, K.
    Schulz, U.
    Gummert, J.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 53 - 53
  • [50] The Effect of Everolimus Initiation and Calcineurin Inhibitor Reduction on Allograft Vasculopathy in Maintenance Heart Transplant Recipients: Results of the NOCTET Trial After 5 Years
    Arora, S.
    Karason, K.
    Eisjaer, H.
    Botker, H.
    Gustafsson, F.
    Saunamaki, K.
    Radegran, G.
    Gude, E.
    Aaberge, L.
    Ueland, T.
    Aukrust, P.
    Solbu, D.
    Gullestad, L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S32 - S32
12345